[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627576":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":58,"collaborators":17,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":17,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":17,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":84,"whyStopped":17,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Boston Children's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Ketamine","EXPERIMENTAL","Single dose of oral ketamine 0.5mg\u002Fkg (max dose of 35mg)",[13],"Drug: Ketamine hydrochloride injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",null,[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ketamine hydrochloride injection","The drug will be compounded using Ketamine vial 10mg\u002Fml. Either the participant will take one Listerine strip prior to drinking the ketamine injection solution and one Listerine strip after or the participant will drink a mixture of cherry syrup and ketamine injection solution together.",[9],[27],"Oral ketamine",{"type":6,"name":15,"description":29,"armGroupLabels":30,"otherNames":17},"The placebo will be prepared sterile water for a total matching volume of what the ketamine solution would have been. Either the participant will take one Listerine strip prior to drinking the ketamine injection solution and one Listerine strip after or the participant will drink a mixture of cherry syrup and ketamine injection solution together.",[15],[32],{"name":33,"affiliation":5,"role":34},"Natasha Archer","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Natasha Archer, MD, MPH","CONTACT","617-355-6000","x8246","natasha.archer@childrens.harvard.edu",[43],{"facility":5,"status":17,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Brookline","Massachusetts","02445","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-71.12116,42.33176,{"lat":53,"lon":52},[56],{"name":33,"role":38,"phone":57,"phoneExt":17,"email":41},"617-632-3023",{"type":34,"investigatorFullName":33,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Clinical Researcher","100627576","phase-3-optimal-timing-of-ketamine-initiation-for-scd-pain-100627576",false,"NCT07450430","Optimal Timing of Ketamine Initiation for SCD Pain","Double-blind, Randomized, Placebo Controlled Study to Evaluate Optimal Timing of Ketamine Initiation","Inclusion Criteria:\n\n* sickle cell disease diagnosis\n* presenting with pain to ED or infusion clinic\n* patient at study site\n* 6 to 24 years old\n\nExclusion Criteria:\n\n* allergy to ketamine\n* severe side effects associated with ketamine\n* unable to consent","ALL","6 Years","24 Years",{"count":71,"type":72},90,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","The goal of this clinical trial is to learn if the use of early ketamine decreases the chance of admission to the hospital in patients with sickle cell disease presenting with pain.\n\nThe main questions this study aims to answer are:\n\n* Does ketamine given within 1 hour of acute care presentation decrease the chance of hospital admission?\n* If admitted, does continuing ketamine in the first few hours of admission decrease opioid use or length of stay compared to those who start it later in the admission?\n\nResearchers will compare the study arm to patients with sickle cell disease who receive placebo within 1 hour of presentation for the first aim.\n\nParticipants will be given ketamine\u002Fplacebo by mouth without 1 hour of presentation.\n\nIf admitted, all participants will be able to start open label IV ketamine upon admission to the floor based on their clinical needs. Participants who end up starting ketamine will be reviewed to determine if early start to ketamine is helpful in reducing opioid use and length of stay.",[78,79],"Sickle Cell Disease","Sickle Cell Crisis",[81,82,83],"sickle cell disease","ketamine","pain","NOT_YET_RECRUITING","2026-03-05",{"date":87,"type":88},"2026-03-09","ACTUAL",{"date":90,"type":72},"2026-02",{"date":92,"type":72},"2030-02",{"name":5,"class":6},1]